Compare · PACB vs RVTY
PACB vs RVTY
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 28.3x PACB ($609.2M).
- Over the past year, PACB is up 5.8% and RVTY is up 63.4% - RVTY leads by 57.6 points.
- RVTY has been more active in the news (7 items in the past 4 weeks vs 3 for PACB).
- PACB has more recent analyst coverage (25 ratings vs 23 for RVTY).
- Company
- Pacific Biosciences of California Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $609.2M
- $17.26B
- 1M return
- +25.72%
- +4.01%
- 1Y return
- +5.79%
- +63.42%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 3
- 7
- Recent ratings
- 25
- 23
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest PACB
- PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 4 filed by Pacific Biosciences of California Inc.
- PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
- UBS resumed coverage on Pacific Biosciences with a new price target
- PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
- Officer Van Oene Mark sold $30,409 worth of shares (26,911 units at $1.13), decreasing direct ownership by 0.98% to 2,705,853 units (SEC Form 4) to satisfy withholding obligation
- Officer Van Oene Mark was granted 489,130 shares, increasing direct ownership by 22% to 2,732,764 units (SEC Form 4)
- SEC Form 10-Q filed by Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery